Baricitinib (LY3009104)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Baricitinib (LY3009104), covering 2026-04-17 to 2026-04-17. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) [Phase 3]